Saturday, March 2, 2013

What when the boundaries blur between VC & PE?

›
My response on the highly thought provoking blog post "Venture Capital 2.0"  by Drug Baron (David Grainger) - posted on 01/Mar/2...
1 comment:
Wednesday, February 27, 2013

Dialog on Drug Baron's post "The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial"

›
The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial By Drug Baron (David Grainger) http://www.tcpinnovation...
Wednesday, February 20, 2013

Has the rise of an Indian sun in drug discovery horizon turned out a no-show? OR is it a mere eclipse?

›
Looking up on google to put together my next post, I typed out the text “ Drug discovery prospects India” and the top most hit was that of...
2 comments:
Sunday, February 10, 2013

USER TRUST, the dope that can't be ignored in the race to monetizing cyber-social engagement – A commentary in light of the recent revamps to LinkedIn user experience

›
Okay, here goes… FEW STATS & STATEMENTS.. With a market cap of over US$16 billion & revenues forecast slated at US$1.4 b...
2 comments:
Sunday, February 3, 2013

Pfizer Venture Investments (PVI) - a quick analysis of portfolio companies, categories

›
Trying to understand the driving factors behind the trends of life science investments in 2012, I was wondering if VC & CVCs behave dif...
1 comment:
Saturday, February 2, 2013

Awards: So what if there are some & some win them?

›
My comment today on the latest blog entry by A VC @ http://www.avc.com/a_vc/2013/02/award-shows.html When I'm in a business and I’m...
Thursday, January 31, 2013

IRR v/s Social Impact: Do financial institutions necessarily go through this dilemma?

›
The news on Times of India Social Impact Awards & what Nicolas Aguzin, chairman and CEO of JP Morgan- Asia-Pacific said during his s...